Refine Search
(0)
(0)
(4)
(4)

Biosimilars in Ophthalmology

In the long term, GlobalData anticipates that biosimilars will be able to maximize commercial potential in the ophthalmology markets due mainly to patent expiry of the marketed anti-VEGF therapies, including Lucentis, Avastin, and Eylea, and hospitals and pharmacies favour of cheaper products, especially in today’s cost-conscious environment. The majority of KOLs interviewed by GlobalData emphasized the belief that payers will likely dictate the necessity for biosimilars as a cheaper option. Overall, the projected total sales of biosimilars in key ophthalmology markets are forecast to reach $2.9bn in 2026.

PharmaPoint: Glaucoma – Global Drug Forecast and Market Analysis to 2026

  • $10,995
  • December 2017
Add to Basket Quick View Add to Saved List

Glaucoma is the leading cause of irreversible vision loss, worldwide. The term glaucoma includes many different diseases, which are associated with differing risk factors, symptoms, treatment, and prognosis. All forms of glaucoma are characteri...

EpiCast Report: Glaucoma – Epidemiology Forecast to 2026

  • $3,995
  • December 2017
Add to Basket Quick View Add to Saved List

Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eye’s optic nerve, resulting in progressive, irreversible vision loss. Glaucoma is one of the leading causes of blindness worldwide, especially in elderly people...

PharmaPoint: Macular Edema – Global Drug Forecast and Market Analysis to 2026

  • $10,995
  • November 2017
Add to Basket Quick View Add to Saved List

ME is a condition characterized by the thickening and swelling (edema) of the macula, which is the area of the retina that is responsible for central vision. The occurrence of ME is highly frequent in diabetics and usually manifests itself as D...

OpportunityAnalyzer: Uveitis Opportunity Analysis and Forecasts to 2026

  • $10,995
  • November 2017
Add to Basket Quick View Add to Saved List

Uveitis is an inflammatory condition of the eye affecting mainly the uvea. It encompasses a heterogeneous collection of disorders characterized by ocular inflammation. Currently, there is only a limited number of approved drugs for the treatmen...